Scottish Enterprise

Lentitek is a biotechnology company focused on developing gene and gene-modified cell therapies, particularly aimed at treating cancer. The company is dedicated to enhancing the accessibility of innovative cures by increasing the yield of lentiviral vectors, which are critical for gene therapy applications. Lentitek employs a proprietary method that utilizes a novel promoter to significantly boost lentiviral production, potentially increasing yields by tenfold or more. This innovative approach not only improves the efficiency of lentivirus production but also aims to reduce overall production costs for healthcare providers, thereby facilitating broader availability of advanced therapeutic options for patients.

Airglove Medical specializes in manufacturing and distributing innovative medical devices. Their flagship product, the Airglove, is a skin warming device that uses LED technology and magnification to enhance vein visibility, facilitating easier and more accurate venipuncture procedures. The device is designed to integrate seamlessly with existing healthcare systems, offering a USB-powered, multi-voltage option for use in various clinical settings, including the NHS.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Novosound Ltd is a company based in Edinburgh, United Kingdom, that specializes in manufacturing printable ultrasound sensors for various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental applications. Founded in 2016, it emerged as the first spin-out from the University of the West of Scotland. Novosound employs innovative thin-film manufacturing techniques to overcome the limitations of traditional ultrasound technology, allowing for the development of highly customizable and scalable ultrasound solutions. The company's offerings include sensors, systems, and software designed to facilitate high-resolution imaging and measurement, particularly in non-destructive testing and medical fields.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Metacarpal specializes in the development of innovative bionic prosthetic hands designed to enhance the quality of life for individuals with limb differences. Their pioneering technology features fully mechanical prostheses capable of variable grips, allowing users to effortlessly switch between different hand positions for various tasks. This adaptability ensures a secure grip on objects of varying shapes and sizes, complemented by a grip lock feature for added stability. By integrating intuitive control mechanisms reminiscent of body-powered devices, Metacarpal aims to provide users with a natural and responsive experience. In addition to serving individuals in developed regions, the company is committed to supplying prosthetics to underprivileged communities in the developing world, addressing a critical need for accessible assistive technology.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Phlo is a digital pharmacy based in London, England, established in January 2019 by Nadeem Sarwar. The company specializes in delivering NHS and private prescriptions directly to patients, focusing on both repeat and acute prescriptions. Phlo's platform allows users to create accounts, manage their medical records, receive prescriptions, and request medications online. By leveraging technology and analytics, Phlo aims to enhance the patient experience, offering real-time, on-demand delivery that saves time and eliminates the need for in-person visits to pharmacies. The service is designed to provide a safe and secure way for patients to access prescription and over-the-counter medications from the comfort of their homes.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, specializing in the development of innovative treatments for various clinical conditions with significant unmet medical needs. Founded in 2010, the company is focused on its lead product, ABL101, which is aimed at managing acute ischaemic stroke. This product incorporates a unique perfluorocarbon technology that carries oxygen to organs and tissues, independent of hemoglobin levels. Aurum also utilizes proprietary image analysis software in conjunction with magnetic resonance imaging to enhance the assessment of stroke patients. The company is in the final stages of preclinical development and plans to initiate clinical studies to evaluate the efficacy and safety of ABL101 soon. Additionally, Aurum is exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia, demonstrating its commitment to addressing diverse health challenges.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Ossur is a global leader in the development, manufacturing, distribution, and marketing of high-technology orthotic and prosthetic devices. Headquartered in Reykjavik, Iceland, the company operates U.S. sales and marketing from Aliso Viejo, California, with additional offices in Vancouver, Canada; Uppsala, Sweden; and Eindhoven, Netherlands. Ossur is committed to enhancing the quality of life for individuals with mobility challenges, dedicating 6-8 percent of its revenue to medical technology research and development. The company also offers extensive educational resources through the Ossur Academy and actively engages in community outreach initiatives and partnerships with non-profit organizations.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which aims to restore key microRNA levels to enhance tendon strength and aid recovery. By targeting the molecular mechanisms that lead to tendinopathy, Causeway Therapeutics seeks to provide effective solutions for managing pain and promoting healing in damaged tendons.

Phlo is a digital pharmacy based in London, England, established in January 2019 by Nadeem Sarwar. The company specializes in delivering NHS and private prescriptions directly to patients, focusing on both repeat and acute prescriptions. Phlo's platform allows users to create accounts, manage their medical records, receive prescriptions, and request medications online. By leveraging technology and analytics, Phlo aims to enhance the patient experience, offering real-time, on-demand delivery that saves time and eliminates the need for in-person visits to pharmacies. The service is designed to provide a safe and secure way for patients to access prescription and over-the-counter medications from the comfort of their homes.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

PneumoWave is focused on developing innovative real-time monitoring solutions for patients with respiratory conditions, enabling them and their healthcare providers to track respiratory rates and performance outside of clinical settings. The company combines proprietary sensor technology with an AI-driven digital therapeutic software platform to enhance patient care. Its technology features advanced algorithms that accurately detect various respiratory adverse events, while a biosensor continuously collects and wirelessly transmits data for analysis. This system includes an alert mechanism that promptly notifies healthcare providers, facilitating early intervention and improving the overall management of respiratory health. By rationalizing medication use and identifying early signs of deterioration, PneumoWave aims to reduce hospital admissions and minimize the need for face-to-face appointments, thereby transforming respiratory care.

The University of Edinburgh, established in 1583, is a prestigious institution located in Edinburgh, United Kingdom. It is renowned globally for its academic excellence, offering a wide range of disciplines, including its renowned Medical School and Law School. As one of Scotland's ancient universities, it is committed to delivering high-quality education, conducting cutting-edge research, and fostering innovation to address global challenges.

Novosound Ltd is a company based in Edinburgh, United Kingdom, that specializes in manufacturing printable ultrasound sensors for various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental applications. Founded in 2016, it emerged as the first spin-out from the University of the West of Scotland. Novosound employs innovative thin-film manufacturing techniques to overcome the limitations of traditional ultrasound technology, allowing for the development of highly customizable and scalable ultrasound solutions. The company's offerings include sensors, systems, and software designed to facilitate high-resolution imaging and measurement, particularly in non-destructive testing and medical fields.

Hearing Diagnostics Limited is a health-tech startup based in Edinburgh, United Kingdom, focused on developing innovative hearing screening and diagnostic products. Incorporated in 2017, the company offers tools such as Audimetroid, which utilizes head motion sensors to facilitate localization-based hearing screenings. These products are designed for use by healthcare professionals, including nurses, audiologists, and otolaryngologists, allowing for objective assessments of hearing loss. The technology aims to provide effective and cost-efficient hearing screenings, employing a spatial paradigm where patients listen to sounds through headphones while utilizing inertia measurement sensors. This approach enables accessible and efficient hearing tests in community settings, addressing the challenges of unmanaged hearing loss and promoting earlier intervention for affected individuals.

Roslin Technologies is an ag-tech and food tech company focused on enhancing protein production through innovative biotechnologies. The company specializes in animal stem cell research, having developed perpetually self-renewing, pluripotent stem cells, which are pivotal for the advancement of cultivated meat products for consumers. Roslin's intellectual property and technological platforms are designed to supply these cell lines and related media formulations to the cultivated meat sector. Additionally, the company aims to leverage its stem cell technology to create cell therapies that address incurable diseases in animals, thereby supporting the meat industry in reducing costs and accelerating market entry.

CardioPrecision Ltd, established in 2007 and based in Glasgow, United Kingdom, specializes in the development of innovative medical devices for invasive cardiovascular surgery. The company has created a patented technology that allows medical professionals to conduct minimally invasive procedures with minimal neck access. Its flagship device is a retractor that illuminates different zones of the operative field, facilitating the various steps of cardiothoracic operations through a short incision in the skin crease of the neck. This advancement enables endoscopic vessel harvesting operators to control the monitor's position and perform procedures from a comfortable, upright posture, ultimately enhancing precision during less invasive aortic valve replacement surgeries.

eMoodie is a technology company that has developed an app designed for ecological momentary assessment research, focusing on mental health, emotions, and socialization patterns in children and adolescents. The app, designed as a research tool, examines symptoms, feelings, and health aspects, including sleep, in older kids, teenagers, and adults. It also enables parents to monitor and mitigate the digital mental impact on their children.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Aiber develops innovative software and medical support systems aimed at enhancing emergency care in challenging environments, such as in the air or at sea. Their solutions leverage Bluetooth sensors to enable wireless monitoring of vital signs, facilitating the identification of patient deterioration or improvement. By providing medical-grade sensors, Aiber empowers crews to manage medical emergencies with confidence and ensures that vital health information is shared with ground-based medical providers. This approach allows flight businesses to deliver consistent and effective care to passengers during flights, supporting international first response efforts on the frontline of emergency care.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Epipole Ltd. is a UK-based company specializing in the design and manufacture of advanced retinal video cameras, known as the EpiCam series. Founded in 2011 and headquartered in Rosyth, the company aims to enhance the early diagnosis and monitoring of retinal diseases, particularly diabetic retinopathy. The EpiCam family includes the EpiCam M, a hand-held digital retinal camera that allows real-time exploration of retinal vasculature; the EpiCam C, which provides an expanded field of view; and the EpiCam V, designed specifically for veterinary use. Additionally, Epipole offers the Model Eye, an optical replica of the human eye for training purposes. Through a network of distributors and online platforms, Epipole aims to revolutionize ophthalmic practice by introducing innovative imaging solutions that improve clinical understanding and patient outcomes.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

PneumoWave is focused on developing innovative real-time monitoring solutions for patients with respiratory conditions, enabling them and their healthcare providers to track respiratory rates and performance outside of clinical settings. The company combines proprietary sensor technology with an AI-driven digital therapeutic software platform to enhance patient care. Its technology features advanced algorithms that accurately detect various respiratory adverse events, while a biosensor continuously collects and wirelessly transmits data for analysis. This system includes an alert mechanism that promptly notifies healthcare providers, facilitating early intervention and improving the overall management of respiratory health. By rationalizing medication use and identifying early signs of deterioration, PneumoWave aims to reduce hospital admissions and minimize the need for face-to-face appointments, thereby transforming respiratory care.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, specializing in the development of innovative treatments for various clinical conditions with significant unmet medical needs. Founded in 2010, the company is focused on its lead product, ABL101, which is aimed at managing acute ischaemic stroke. This product incorporates a unique perfluorocarbon technology that carries oxygen to organs and tissues, independent of hemoglobin levels. Aurum also utilizes proprietary image analysis software in conjunction with magnetic resonance imaging to enhance the assessment of stroke patients. The company is in the final stages of preclinical development and plans to initiate clinical studies to evaluate the efficacy and safety of ABL101 soon. Additionally, Aurum is exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia, demonstrating its commitment to addressing diverse health challenges.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Asklepios BioPharmaceutical is a biotechnology company focused on developing adeno-associated virus (AAV) gene therapies aimed at treating genetic disorders and rare diseases. Established in 2001 and headquartered in Research Triangle Park, North Carolina, the company possesses proprietary AAV technology and manufacturing capabilities, as well as a robust pipeline of clinical programs. Its pipeline includes clinical-stage therapies for Pompe disease and congestive heart failure, alongside a diverse array of preclinical candidates targeting neuromuscular and central nervous system diseases. Additionally, Asklepios has out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform features Pro10, a proprietary cell line manufacturing process, complemented by an extensive library of AAV capsids and promoters, supporting advancements in genetic medicine through global research collaborations and innovative delivery methods.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.

Epipole Ltd. is a UK-based company specializing in the design and manufacture of advanced retinal video cameras, known as the EpiCam series. Founded in 2011 and headquartered in Rosyth, the company aims to enhance the early diagnosis and monitoring of retinal diseases, particularly diabetic retinopathy. The EpiCam family includes the EpiCam M, a hand-held digital retinal camera that allows real-time exploration of retinal vasculature; the EpiCam C, which provides an expanded field of view; and the EpiCam V, designed specifically for veterinary use. Additionally, Epipole offers the Model Eye, an optical replica of the human eye for training purposes. Through a network of distributors and online platforms, Epipole aims to revolutionize ophthalmic practice by introducing innovative imaging solutions that improve clinical understanding and patient outcomes.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

EnMovi is a Medical technology firm.

Novosound Ltd is a company based in Edinburgh, United Kingdom, that specializes in manufacturing printable ultrasound sensors for various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental applications. Founded in 2016, it emerged as the first spin-out from the University of the West of Scotland. Novosound employs innovative thin-film manufacturing techniques to overcome the limitations of traditional ultrasound technology, allowing for the development of highly customizable and scalable ultrasound solutions. The company's offerings include sensors, systems, and software designed to facilitate high-resolution imaging and measurement, particularly in non-destructive testing and medical fields.

Aiber develops innovative software and medical support systems aimed at enhancing emergency care in challenging environments, such as in the air or at sea. Their solutions leverage Bluetooth sensors to enable wireless monitoring of vital signs, facilitating the identification of patient deterioration or improvement. By providing medical-grade sensors, Aiber empowers crews to manage medical emergencies with confidence and ensures that vital health information is shared with ground-based medical providers. This approach allows flight businesses to deliver consistent and effective care to passengers during flights, supporting international first response efforts on the frontline of emergency care.

Aiber develops innovative software and medical support systems aimed at enhancing emergency care in challenging environments, such as in the air or at sea. Their solutions leverage Bluetooth sensors to enable wireless monitoring of vital signs, facilitating the identification of patient deterioration or improvement. By providing medical-grade sensors, Aiber empowers crews to manage medical emergencies with confidence and ensures that vital health information is shared with ground-based medical providers. This approach allows flight businesses to deliver consistent and effective care to passengers during flights, supporting international first response efforts on the frontline of emergency care.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Novosound Ltd is a company based in Edinburgh, United Kingdom, that specializes in manufacturing printable ultrasound sensors for various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental applications. Founded in 2016, it emerged as the first spin-out from the University of the West of Scotland. Novosound employs innovative thin-film manufacturing techniques to overcome the limitations of traditional ultrasound technology, allowing for the development of highly customizable and scalable ultrasound solutions. The company's offerings include sensors, systems, and software designed to facilitate high-resolution imaging and measurement, particularly in non-destructive testing and medical fields.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Canon Medical Research is a medical software research and development center that creates game-changing technologies and valuable intellectual property for Canon Medical Systems. Its teams create next-generation medical imaging software that integrates with Canon Medical scanners and other diagnostic healthcare solutions installed in hospitals and health centers around the world.

Novosound Ltd is a company based in Edinburgh, United Kingdom, that specializes in manufacturing printable ultrasound sensors for various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental applications. Founded in 2016, it emerged as the first spin-out from the University of the West of Scotland. Novosound employs innovative thin-film manufacturing techniques to overcome the limitations of traditional ultrasound technology, allowing for the development of highly customizable and scalable ultrasound solutions. The company's offerings include sensors, systems, and software designed to facilitate high-resolution imaging and measurement, particularly in non-destructive testing and medical fields.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which aims to restore key microRNA levels to enhance tendon strength and aid recovery. By targeting the molecular mechanisms that lead to tendinopathy, Causeway Therapeutics seeks to provide effective solutions for managing pain and promoting healing in damaged tendons.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.

MOFgen Ltd is a pioneering company that specializes in the commercialization of metal-organic frameworks (MOFs) for medical and therapeutic applications. Originating as a spin-out from the University of St Andrews, the company leverages patented technology developed by renowned porous material scientist Prof Russell Morris. MOFgen focuses on designing, manufacturing, and formulating MOFs to create innovative solutions for healthcare challenges. Its products include powdery solids with microscopic pores capable of incorporating antibacterial agents, wound healing compounds, and anti-thrombotic substances. These advanced coatings for medical devices aim to enhance patient care by reducing infection rates and minimizing the need for prolonged hospital stays. Through collaboration with various partners, MOFgen is committed to developing tailored solutions for issues such as healthcare-associated infections, bacterial resistance, chronic wounds, and arterial access.

Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, specializing in the development of innovative treatments for various clinical conditions with significant unmet medical needs. Founded in 2010, the company is focused on its lead product, ABL101, which is aimed at managing acute ischaemic stroke. This product incorporates a unique perfluorocarbon technology that carries oxygen to organs and tissues, independent of hemoglobin levels. Aurum also utilizes proprietary image analysis software in conjunction with magnetic resonance imaging to enhance the assessment of stroke patients. The company is in the final stages of preclinical development and plans to initiate clinical studies to evaluate the efficacy and safety of ABL101 soon. Additionally, Aurum is exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia, demonstrating its commitment to addressing diverse health challenges.

Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development of tunable peptide hydrogels for various applications in cell culture research, including toxicity screening, cancer research, and potential therapeutic uses. Founded in 2012, the company provides hydrogels that mimic the physical and chemical properties of natural tissues, allowing researchers to grow and manipulate cells in a realistic three-dimensional environment. These products are designed to meet the specific requirements of different cell types, offering a viable alternative to traditional animal testing and other 3D cell culture methods. Biogelx's patented hydrogel technologies are marketed in the US, Europe, and Asia, catering to academic institutions, medical researchers, and pharmaceutical companies engaged in drug development and regenerative medicine.

Clyde Biosciences, established in 2012 and headquartered in Glasgow, UK, specializes in providing cardiac cell analysis solutions for the pharmaceutical and biotechnology industries, both domestically and internationally. The company's core offerings include cellOPTIQ, an optical action potential assay, and XTENDSR, a solution for measuring drug-induced changes on cardiac sarcoplasmic reticulum function. These solutions enable clients to gain insights into the mechanisms and effects of drug compounds on human cells, aiding in the evaluation of drug toxicity and cardiotoxicity risk during the research and development phase.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.

Relitect Limited is a biotechnology company based in Motherwell, United Kingdom, founded in 2014. The company focuses on developing a novel assay platform for the label-free electrochemical detection of binding events. This proprietary technology enables the analysis of proteins, small molecules, and nucleic acids, making it applicable in clinical diagnostics and life sciences. Relitect's approach allows for the detection of highly sensitive biomarkers and other analytes in a multiplexed format, which utilizes small sample volumes and minimizes sample interference. By eliminating the potential for labeled reagent cross-talk, Relitect’s technology offers significant advantages for diagnostic and research applications, enhancing the capabilities of clinical diagnostics and life science companies.

DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, specializing in the detection of nucleic acids and single nucleotide polymorphisms (SNPs). Established in 2010 as a spin-out from the University of Edinburgh, the company focuses on commercializing a groundbreaking chemical-based system that differentiates itself from existing enzymatic methods. DestiNA Genomics provides reagents and probes for the detection of nucleic acids and mutations, supporting drug development and profiling in areas such as drug sensitivity, inherited diseases, and infectious diseases. The company aims to launch a completely PCR-free system for nucleic acid analysis, particularly effective for direct detection of micro-RNAs. Additionally, DestiNA Genomics collaborates with trade partners to integrate its technology into various detection platforms, and has established a Spanish subsidiary, DestiNA Genomica SL, to further develop its offerings in Spain with support from a grant aimed at promoting R&D.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.

Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.